Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly.
Here are are a few highlights from this week:
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial (JAMA) - In children with ALL, pre-HSCT consolidation with blinatumomab improves EFS as compared to standard chemotherapy, as reported in one of the two papers published on JAMA this week.
- Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial (JAMA) - A non statistically significant improvement in DFS is associated with blinatumomab vs. chemotherapy consolidation, according to this randomized phase 3 trial in ALL young patients
- Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study (Br J Haematol) - Comparable clinical activity, with low infusion-related reaction rates and reduced administration time, can be obtained by subcutaneous daratumomab as compared to the standard intravenous drug.
- Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma (Blood) - Although efficacy of isatuximab was demostrated in R/R MM patients, increased response rates and survival outcomes with no detrimental effect on safety can be obtained with the addition of dexamethasone.
You can access our complete resource library of scientific publications here.
Last Updated on Thursday 25 March 2021.